Cancer therapies dominate 40% of the global clinical pipeline, and the field of oncology is leading the precision medicine revolution.
According to a 2016 industry survey, 80% of respondents agreed that Phase I studies are becoming more complex.
When optimizing your study practice, it is vital to evaluate every trial phase in context.
Nearly 20 years ago Medidata was built around modernizing data capture and management, which ultimately became Rave. Today, we can confidently say we’re so much more than that.